Citations

Showing 10 of 108083 citations.

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
Skljarevski, Vladimir, Oakes, Tina M. , Zhang, Qi , Ferguson, Margaret B., Martinez, James M. , Camporeale, Angelo, Johnson, Kirk W. , Shan, Qiu-Ling, Carter, Jeffrey, Schacht, Aaron L., Goadsby, Peter J. , Dodick, David W.

Mayo Clinic

JAMA Neurology | December 18, 2017 | Volume: 75 | Issue: 2 | Pages: 187

10.1001/jamaneurol.2017.3859 | PMID 29255900 Get It

Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature
Dioverti, M. Veronica , Saleh, Omar Abu , Tande, Aaron J. , Dioverti, Maria Veronica, Abu Saleh, Omar M, Tande, Aaron , Dioverti, Maria Veronica

Mayo Clinic

Infectious Diseases | December 18, 2017 | Volume: 50 | Issue: 5 | Pages: 381-387

10.1080/23744235.2017.1390248 | PMID 29251529 Get It

VaDiR: an integrated approach to Variant Detection in RNA
Neums, Lisa , Suenaga, Seiji, Beyerlein, Peter, Anders, Sara, Koestler, Devin C. , Mariani, Andrea , Chien, Jeremy , Chien, Jeremey

Mayo Clinic

GigaScience | December 18, 2017 | Volume: 7 | Issue: 2 | Pages: No page available

10.1093/gigascience/gix122 | PMID 29267927 Get It

Abstract Background Advances in next-generation DNA sequencing technologies are now enabling detailed characterization of sequence variations in cancer genomes. With whole-genome sequencing, variations in coding and non-coding sequences can be discovered. But the cost associated with it is currently limiting its general use in research. Whole-exome sequencing is used to characterize sequence variations in coding regions, but the cost associated with capture reagents and biases in capture rate limit its full use in research. Additional limitations include uncertainty in assigning the functional significance of the mutations when these mutations are observed in the non-coding region or in genes that are not expressed in cancer tissue. Results We investigated the feasibility of uncovering mutations from expressed genes using RNA sequencing datasets with a method called Variant Detection in RNA(VaDiR) that integrates 3 variant callers, namely: SNPiR, RVBoost, and MuTect2. The combination of all 3 methods, which we called Tier 1 variants, produced the highest precision with true positive mutations from RNA-seq that could be validated at the DNA level. We also found that the integration of Tier 1 variants with those called by MuTect2 and SNPiR produced the highest recall with acceptable precision. Finally, we observed a higher rate of mutation discovery in genes that are expressed at higher levels. Conclusions Our method, VaDiR, provides a possibility of uncovering mutations from RNA sequencing datasets that could be useful in further functional analysis. In addition, our approach allows orthogonal validation of DNA-based mutation discovery by providing complementary sequence variation analysis from paired RNA/DNA sequencing datasets.
Single-cycle adenovirus vectors in the current vaccine landscape
Barry, Michael A. , Barry, Michael, Barry, Michael A

Mayo Clinic

Expert Review of Vaccines | December 18, 2017 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.1080/14760584.2018.1419067 | PMID 29251011 Get It

Impairment of amyloid precursor protein alpha-processing in cerebral microvessels of type 1 diabetic mice
He, Tongrong , Sun, Ruohan , Santhanam, Anantha V., Lü, Tong , Katušić, Zvonimir S. , Santhanam, Anantha Vr, d'Uscio, Livius V, Lu, Tong , Santhanam, Anantha Vijay R., d’Uscio, Livius V.

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | December 18, 2017 | Volume: 39 | Issue: 6 | Pages: 1085-1098

10.1177/0271678x17746981 | PMID 29251519 Get It

The mechanisms underlying dysfunction of cerebral microvasculature induced by type 1 diabetes (T1D) are not fully understood. We hypothesized that in cerebral microvascular endothelium, α-processing of amyloid precursor protein (APP) is impaired by T1D. In cerebral microvessels derived from streptozotocin (STZ)-induced T1D mice protein levels of APP and its α-processing enzyme, a disintegrin and metalloprotease 10 (ADAM10) were significantly decreased, along with down-regulation of adenylate cyclase 3 (AC3) and enhanced production of thromboxane A 2 (TXA 2 ). In vitro studies in human brain microvascular endothelial cells (BMECs) revealed that knockdown of AC3 significantly suppressed ADAM10 protein levels, and that activation of TXA 2 receptor decreased APP expression. Furthermore, levels of soluble APPα (sAPPα, a product of α-processing of APP) were significantly reduced in hippocampus of T1D mice. In contrast, amyloidogenic processing of APP was not affected by T1D in both cerebral microvessels and hippocampus. Most notably, studies in endothelial specific APP knockout mice established that genetic inactivation of APP in endothelium was sufficient to significantly reduce sAPPα levels in the hippocampus. In aggregate, our findings suggest that T1D impairs non-amyloidogenic processing of APP in cerebral microvessels. This may exert detrimental effect on local concentration of neuroprotective molecule, sAPPα, in the hippocampus.
Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database
Pruett, Janis , Lickert, Cassandra A., Berger, Ariel , Drake, William, Burger, Charles D. , Murphy, Brian R. , Berger, Ariel

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | December 18, 2017 | Volume: 24 | Issue: 3 | Pages: 291-302

10.18553/jmcp.2017.17228 | PMID 29406840 Get It

Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations
Lightner, Amy L. , McKenna, Nicholas P. , Raffals, Laura E. , Loftus, Edward V. , Mathis, Kellie L. , Lightner, A L , Loftus, Edward V , Tse, Chung Sang , McKenna, Nicholas P

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 18, 2017 | Volume: 47 | Issue: 5 | Pages: 573-580

10.1111/apt.14459 | PMID 29250800 Get It

SummaryBackgroundUp to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post‐operative complications.AimWe sought to compare 30‐day postoperative infectious complication rate among vedolizumab‐treated Crohn's disease patients vs those who had received TNFα inhibitors or no biologic therapy.MethodsA retrospective review of all Crohn's disease patients who received vedolizumab within 12 weeks of a major abdominal or pelvic operation was performed. Two control cohorts consisted of Crohn's disease patients treated with TNFα inhibitors or no biologic therapy.ResultsOne hundred Crohn's disease patients received vedolizumab within 12 weeks of an abdominal operation. Vedolizumab‐treated patients underwent an equivalent rate of laparoscopic surgery (P = .25), had fewer anastomoses performed (P = .0002), and had equally frequent diversion in the setting of anastomoses (P = .47). Thirty‐two vedolizumab‐treated patients experienced postoperative infectious complications (32%), 26 of which were surgical site infections (26%). The vedolizumab‐treated group experienced no difference in nonsurgical site infections (6% vs 5% anti‐TNFα and 2% nonbiologic; P = .34), but significantly higher rates of surgical site infections (26% vs 8% and 11%; P < .001). On univariate and multivariate analysis, exposure to vedolizumab remained a significant predictor of postoperative surgical site infection (P < .001 and P = .002).ConclusionsTwenty‐six per cent of Crohn's disease patients who received vedolizumab within 12 weeks prior to a major abdominal operation experienced a 30‐day postoperative surgical site infection, significantly higher than that of patients receiving TNFα inhibitors or no biologic therapy. Vedolizumab within 12 weeks of surgery remained a predictor of 30‐day postoperative surgical site infection on multivariable analysis. While vedolizumab‐treated Crohn's disease patients may be a sicker cohort of patients, it is important to consider these findings with regard to preoperative counselling, operative timing and primary closure of wounds.
Midlife cardiovascular health and 20‐year cognitive decline: Atherosclerosis Risk in Communities Study results
González, Héctor M. , Tarraf, Wassim , Harrison, Kimystian L. , Windham, B. Gwen , Tingle, Jonathan V., Griswold, Michael , Heiss, Gerardo , Gonzalez, Hector M , Alonso, Álvaro , Knopman, David S. , Mosley, Thomas H.

Mayo Clinic

Alzheimer's & Dementia | December 18, 2017 | Volume: 14 | Issue: 5 | Pages: 579-589

10.1016/j.jalz.2017.11.002 | PMID 29268079 Get It

AbstractIntroductionThe aim was to examine associations between midlife cardiovascular health (CVH) and 20‐year cognitive decline among blacks and whites.MethodsMidlife CVH metrics (American Heart Association's Life's Simple 7) were calculated and examined in relation to midlife and 20‐year change in cognitive function among 13,270 whites and blacks from the Atherosclerosis Risk in Communities Cohort Study. We used linear mixed models to estimate adjusted associations of midlife CVH with midlife cognitive status and change.ResultsHigher midlife (Life's Simple 7) scores and individual metrics, particularly blood pressure and glucose, were associated with better midlife cognition and reduced 20‐year decline. Midlife CVH 20‐year neuroprotection was more pronounced among whites than blacks.DiscussionBetter midlife CVH was associated with higher midlife and reduced decline in cognitive function 20 years later. However, the benefits of midlife CVH on cognition were stronger for whites than for blacks. Our findings suggest that improved midlife CVH may promote enduring cognitive health.
Surveillance for and Discovery of Borrelia Species in US Patients Suspected of Tickborne Illness
Kingry, Luke C. , Anacker, Melissa , Pritt, Bobbi S. , Bjork, Jenna , Respicio-Kingry, Laurel, Liu, Gong‐Ping , Sheldon, Sarah W., Boxrud, David, Strain, Anna K., Oatman, Stephanie, Berry, Jon, Sloan, Lynne M., Mead, Paul S. , Neitzel, David F., Kugeler, Kiersten J. , Petersen, Jeannine M., Pritt, Bobbi, Sloan, Lynne, Kingry, Luke , Pritt, Bobbi S , Berry, Jonathan

Mayo Clinic

Clinical Infectious Diseases | December 17, 2017 | Volume: 66 | Issue: 12 | Pages: 1864-1871

10.1093/cid/cix1107 | PMID 29272385 Get It